EUCTR2016-001106-42-DE进行中（未招募）1 期
Double-blind, randomised clinical study comparing efficacy and safety of Calcipotriol 50 µg/g_Betamethasone 0.5 mg/g Gel (Test) vs. Daivobet(R) Gel (Reference) vs. Vehicle in patients with scalp psoriasis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 225
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Women and men = 18 years of age
- •Written consent to study participation after patient information by the investigator
- •Diagnosis of scalp psoriasis vulgaris” according to generally accepted criteria
- •Extent of scalp psoriasis involving at least 20% of the total scalp area
- •For the score values of the activity parameters erythema, desquamation, induration and pruritus (each assessed on a scale from 0 to 3) the following applies:
- •o Sum score of all four parameters = 6 and
- •o Desquamation and erythema = 4 and
- •o Desquamation = 2.
- •For women of childbearing potential: Application of an efficient contraceptive method during the whole study
- •For women of childbearing potential: Pregnancy test with negative result prior to study start
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 225
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative or pustular psoriasis
- •Systemic therapy of psoriasis within the last 4 weeks before study inclusion
- •Any topical treatment or physical therapy (e.g. UV radiation, retinoids, corticosteroids) of scalp psoriasis within the last 2 weeks before study inclusion
- •Known intolerance or hypersensitivity against calcipotriol, betamethasone or other glucocorticoids or any of the other ingredients in the study medication
- •History of psoriasis unresponsive to topical treatment
- •Current or past history of hypercalcemia, vitamin D toxicity, severe renal insufficiency, or severe hepatic disorders
- •Presence of any of the following skin conditions in the treatment area: viral infections (e.g. herpes simplex, herpes zoster, varicella), fungal and bacterial skin infections, parasitic infections, skin manifestions in relation to tuberculosis, perioral dermatitis, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne vulgaris, acne rosacea, rosacea, ulcers and wounds
- •Other inflammatory skin disease in the treatment area that may confound the evaluation of the scalp psoriasis (e.g. atopic dermatitis, contact dermatitis, tinea capitis)
- •Presence of pigmentation, extensive scarring, pigmented lesions or sunburn in the treatment area, which could interfere with the rating of efficacy and safety parameters
- •Other severe acute or chronic concomitant disease with severe impairment of the general condition
- •Other concomitant diseases which may - taking the present knowledge into account - influence the parameters evaluated in the study in a way that an objective evaluation would be impossible
- •Other concomitant medication which may - taking the present knowledge into account - influence the methods of measurement used in this study or the resulting data
- •Reasonable doubt concerning the co-operation of the patient
- •Participation in another clinical study within the last 30 days prior to inclusion in this study
- •Participation in this study at an earlier date
- •Women with existing or intended pregnancy or during lactation
研究者
相似试验
进行中（未招募）
1 期
Clincal study to compare the therapeutic effects of two ointments with active substances betamethasone dipropionate and salicylic acid and of one ointment without active substance for patients with chronic stable plaque psoriasisEUCTR2020-004081-19-DEDermapharm AG306
进行中（未招募）
1 期
Clinical study to compare two creams with the active substance gentamicin and betamethason and one cream without active substance for patients with bacterial infected eczemaEUCTR2014-005518-44-DEDermapharm AG400
招募中
1 期
Clinical study to compare two cutaneous ointments with the active substance methylprednisolone aceponate 0.1% and one cutaneous ointment without active substance for patients with atopic dermatitisCTIS2024-514548-10-01Dermapharm AG330
进行中（未招募）
1 期
Clinical study to compare the therapeutic effects of two creams with the active substances miconazole and fluprednidene and of one cream without active substance for patients with moderate to severely inflamed infection of the skin through yeast fungi.moderate to severely inflamed candidiasis of the skinMedDRA version: 19.0Level: LLTClassification code 10007159Term: Candidiasis of skin and nailsSystem Organ Class: 100000004862EUCTR2015-005707-92-DEDermapharm AG340
招募中
1 期
Clinical study to compare two cutaneous creams with the active substance methylprednisolone aceponate 0.1% and one cutaneous cream without active substance for patients with atopic dermatitisCTIS2024-511390-30-00Dermapharm AG330